Breakthrough in Cancer Gene Therapy: In Vivo Chimeric Antigen Receptor (CAR)-T Cell Therapy Gains Momentum

Strategic Insights -

Recent advances in virology, RNA medicines, and nanotechnology have revolutionized the field of cancer gene therapy, particularly in the development of in vivo chimeric antigen receptor (CAR)-T cell therapy. This innovative approach has shown promising results in clinical studies, demonstrating efficient transduction, sustained CAR expression, and initial signs of antitumour activity. By eliminating the need for ex vivo manipulation and chemotherapeutic conditioning, this strategy has the potential to make CAR-T cell therapies more accessible and effective for treating not only blood cancers but also autoimmune diseases such as systemic lupus erythematosus.

Key Takeaways:

  • In vivo CAR-T cell engineering has overcome challenges in manufacturing, production capacity, and clinical performance by generating CAR-T cells directly inside the patient's body.
  • Recent advances in virology, RNA medicines, and nanotechnology have enabled the development of targeted delivery systems, such as lentiviral vectors and lipid nanoparticles, to introduce CAR-encoding genetic material into endogenous T cells.
  • Early clinical studies have shown efficient transduction, sustained CAR expression, and initial signs of antitumour activity, establishing proof of concept for this approach.
  • The use of in vivo CAR-T cell therapy could enable the wider application of CAR-T cell therapies to autoimmune diseases, such as systemic lupus erythematosus, where ex vivo CAR-T cell therapies have shown strong promise.
  • Researchers have adapted RNA delivered by lipid nanoparticles and engineered viral vectors to develop more broadly applicable, scalable, safe, and effective CAR-T cell therapies.
  • The development of in vivo CAR-T cell therapy has the potential to transform the outcomes of patients with haematological malignancies and autoimmune diseases.

Statistics:

  • 2025: Year in which the research findings on biotechnology-cancer gene therapy was discussed in a new report.
  • 13: Page number on which the news report was published.
  • 14197: Postal code of Berlin, Germany, where the publisher's contact information for the journal Nature Reviews Drug Discovery is located.
  • 1,400 words: Estimated length of the research article in Nature Reviews Drug Discovery.
  • 2025: Year in which the journal Nature Reviews Drug Discovery can be contacted at Nature Portfolio, Heidelberger Platz 3, Berlin.

Sources:

  • Research titled "In vivo chimeric antigen receptor (CAR)-T cell therapy" was discussed in a new report.
  • NewsRx, October 15, 2025: Published the news report "Findings from Adrian Bot and Co-Researchers in the Area of Cancer Gene Therapy Reported [In vivo chimeric antigen receptor (CAR)-T cell therapy]."
  • Nature Reviews Drug Discovery, 2025: Published the research article on in vivo chimeric antigen receptor (CAR)-T cell therapy.
  • Adrian Bot, Capstan Therapeutics, San Diego, CA, United States: Additional information may be obtained from this researcher.
  • Andrew Scharenberg, Kevin Friedman, Lin Guey, Robert Hofmeister, James I. Andorko, Michael Klichinsky, Frank Neumann, Jagesh V. Shah, Andrew J. Swayer, Kyle Trudeau, Drew Weissman, Matthias T. Stephan, Christian J. Buchholz, and Carl H. June: Co-authors of the research article in Nature Reviews Drug Discovery.
  • Nature Portfolio, Heidelberger Platz 3, Berlin, 14197, Germany: Publisher's contact information for the journal Nature Reviews Drug Discovery.